| Literature DB >> 20300402 |
Raman Chawla1, Rakesh Kumar Sharma, Deepali Madaan, Neha Dubey, Rajesh Arora, Rajeev Goel, Shefali Singh, Vinod Kaushik, Pankaj Kumar Singh, Vivek Chabbra, Janak Raj Bhardwaj.
Abstract
Management of flu pandemic is a perpetual challenge for the medical fraternity since time immemorial. Animal to human transmission has been observed thrice in the last century within an average range of 11-39 years of antigenic recycling. The recent outbreak of influenza A (H1N1, also termed as swine flu), first reported in Mexico on April 26, 2009, occurred in the forty first year since last reported flu pandemic (July 1968). Within less than 50 days, it has assumed pandemic proportions (phase VI) affecting over 76 countries with 163 deaths/35,928 cases (as on 15(th) June 2009). It indicated the re-emergence of genetically reassorted virus having strains endemic to humans, swine and avian (H5N1). The World Health Organisation (WHO) member states have already pulled up their socks and geared up to combat such criticalities. Earlier outbreaks of avian flu (H5N1) in different countries led WHO to develop pandemic preparedness strategies with national/regional plans on pandemic preparedness. Numerous factors related to climatic conditions, socio-economic strata, governance and sharing of information/logistics at all levels have been considered critical indicators in monitoring the dynamics of escalation towards a pandemic situation.The National Disaster Management Authority (NDMA), Government of India, with the active cooperation of UN agencies and other stakeholders/experts has formulated a concept paper on role of nonhealth service providers during pandemics in April 2008 and released national guidelines - management of biological disasters in July 2008. These guidelines enumerate that the success of medical management endeavors like pharmaceutical (anti-viral Oseltamivir and Zanamivir therapies), nonpharmaceutical interventions and vaccination development etc., largely depends on level of resistance offered by mutagenic viral strain and rationale use of pharmaco therapeutic interventions. This article describes the mitigation approach to combat flu pandemic with its effective implementation at national, state and local levels.Entities:
Keywords: Anti-viral therapies; Flu; H1N1; H5N1; Pandemics; Vaccination
Year: 2009 PMID: 20300402 PMCID: PMC2840954 DOI: 10.4103/0974-777X.56258
Source DB: PubMed Journal: J Glob Infect Dis ISSN: 0974-777X
Emergence and re-emergence of influenza virus in 20-21st century
| Period | Influenza virus A | Observed global phenomenon |
|---|---|---|
| ≈1889- 1901 | H2N2 | Retrospective analysis of sera collected from individuals born as early as 1857; caused 1889–1892 pandemic. Mortality rate were 10%, 45% and 45% in Jan-Mar, 1890; Mar-Jun, 1891 and; Dec- Mar, 1892 respectively in London[ |
| ≈1900 to 1918 | H3N8 | Mild pandemic in 1900 |
| ≈1918- 1919 | H1N1 | 1918-1919 Influenza Outbreak |
| 1957-1958 | H2N2 | Antigenic recycling and replacement of A/H1N1. Mortality rate were 43%, 28% and 29% in Oct, 1957; April, 1960 and; Oc, 1962Apr, 1963 respectively in United States[ |
| 1968-1969 | H3N2 | Antigenic recycling and replacement of A/H2N2 Mortality rate were 15% and 85% in March, 1968 and; Jan, 1969 respectively in England and Wales[ |
| 1977 | H1N1 | Re-emergence of virus after 20 years of silence and also co-circulation of A/H3N2; Pandemic alerts in military barracks of USA control limited its spread preventing a pandemic by mass vaccination program |
| 1997 | H5N1 | Novel pathogen emergence in the persons exposed to infected poultry in Hong Kong; no significant human transmission |
| 1999 | H9N2 | Two children exhibit influenza like symptoms due to the causative agent similar to A/H5N1 and possessed avian origin ∼ indicators for occurrence of pandemic |
| 1999-2007 | H5N1 | Re-emergence as avian epidemic in different countries and in India, six-to-seven states were severely affected during different time periods; however their spread was controlled by stringent measures |
| 2009 | H1N1 | Emergence of H1N1 virus by genetic reassortment of endemic strain of human, avian flu and swine flu caused a pandemic situation |
Severe global pandemic outbreak
Figure 1Global pandemic waves in 20th century
Figure 2Composition of three pandemic periods (with six phases) suggested by WHO and corresponding mitigation strategy- H1N1 Pandemic'09 reached level VI
Figure 3aRate of increase in severity of H1N1 infection (difference in number of deaths on n+10th day- nth day) globally with increasing number of countries being affected vs. time scale of 50 days (26th April- 15th June, 2009). Inset: rate of spread (difference in number of cases on n+10th day- nth day) at the same time scale (WHO update number- 12, 18, 30, 39, 44 and 49).
Figure 3bCountrywide differences in number of deaths / number of confirmed cases of four major countries with maximal number of deaths with respect to global severity index vs. time scale of 50 days (26th April- 15th June, 2009) (WHO update number- 12, 18, 30, 39, 44 and 49).
Figure 3cRatio of increase in number of confirmed cases of H1N1 infection (number of cases on n+10th day / nth day) at global, Mexico and US at a time scale of 50 days (26th April- 15th June, 2009). Inset: expected rise in number of cases in India in next 50 days based on the average ratio of increase of global, US and Mexico spread in last 50 days with starting point of officially reported 16 confirmed cases in India (WHO update- 49).
Some important vaccines developed for medical management of pandemics[48–50]
| Year | Industry | Vaccine type | Brand name | Salient feature(s) |
|---|---|---|---|---|
| 2004 | Sanofi Pasteur | Inactivated vaccine | - | It is an inactivated vaccine made from an H5N1 virus isolated in southeast Asia in 2004. Vaccine is produced from virus grown in fertile hen eggs and inactivated by either formaldehyde or beta – propiolctone. It is given by intramuscular injection. |
| 2006 | MedImmune | Live attenuated influenza vaccine (LAIV) | MedImmue FluMist R influenza vaccine | This vaccine is based on combination of modified protein derived from virulent H5N1 flu virus with protein from an attenuated flu strain. LAIV has been license by FDA in 2003. It contain live but attenuated (weakened) influenza virus. It is sprayed into nostril instead of injected into muscle. |
| 2008 | - | Cell culture vaccine | - | Vaccine is created by using cell of monkeys instead of chicken's egg which reduces the time of development of vaccine. |
| 2009 | - | Recombinant vaccine | - | Use of Human Monoclonal antibodies that neutralize different strain of influenza A virus. Subunit influenza vaccines have been prepared from recombinant haemagglutin and neuraminidase protein expressed in insect cells by baculoviruses. |
| 2009 | NOVAVAX | DNA vaccinevirus like particle (VLP) vaccine candidate | - | Provide broad protection against strains of Avian Infiuenza, mainly 3 strains are used A/Qinghai(clade2.2),aaA. It present promising approach to vaccination, evoking full range of immune response. DNA vaccines with constructs encoding the nucleoprotein(NP), haemagglutin, neuraminidase, matrix protein 1(M1) and non structural protein 1 of influenza virus. |
| 2009 | Delsite Biotechnologies | Live attenuated vaccine | Gelvac TM Nasal powder | It is preservative and adjuvant free and allows needle free administration and it reduce the cost of stockpiling of strategic vaccine. |
Figure 4Components of suggested business continuity plans for pandemic preparedness
Role of non-health service providers
| Non-health sectors | Service providers | Composition and roles |
|---|---|---|
| Financial services | Banks, financial institutions, stock exchange etc | Maintenance of bare minimum financial services with inherent mechanism to ease control |
| Utilities, personal service | Electricity, water, food, telecoms, postal service, retailing (catering for the needs of the most vulnerable) | Contingency plans to provide services in integrated manner |
| Transportation-logistics, business, leisure: supply system | Air, sea, rail, ports, pilgrimages, sports and other events, tourism | Key control for all services, special plans to provide assistance in managing absenteeism |
| Government, security and armed forces | Public service, rule of law, judiciary and correction, private security, respect for rights | Provide framework, ease on regulations, stringent control by applying emergency laws in place |
| Information and management | Transparency, strategic communication, broadcast and print, internet | Economic backbone and strategic business continuity planning is necessary |
| Environment and hygiene | Cleaning, maintenance, refuse management, wildlife | Needs to place to prevent spread of infection |
| Food and livestock production | Growing, processing, marketing and distribution of animal meat for human consumption | Basic need requires replenishment through stores stocks, if necessary |